Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Accounts Payables: 2017-2025

Historic Accounts Payables for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $22.9 million.

  • Protagonist Therapeutics' Accounts Payables rose 10.27% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 10.27%. This contributed to the annual value of $23.7 million for FY2024, which is 22.39% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Accounts Payables of $22.9 million as of Q3 2025, which was up 48.52% from $15.4 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Accounts Payables ranged from a high of $37.7 million in Q4 2021 and a low of $11.8 million during Q1 2025.
  • In the last 3 years, Protagonist Therapeutics' Accounts Payables had a median value of $19.4 million in 2023 and averaged $18.8 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 113.05% in 2021, then crashed by 49.54% in 2023.
  • Protagonist Therapeutics' Accounts Payables (Quarterly) stood at $37.7 million in 2021, then slumped by 33.83% to $25.0 million in 2022, then fell by 22.43% to $19.4 million in 2023, then increased by 22.39% to $23.7 million in 2024, then increased by 10.27% to $22.9 million in 2025.
  • Its last three reported values are $22.9 million in Q3 2025, $15.4 million for Q2 2025, and $11.8 million during Q1 2025.